GRNOPC1: the world's first embryonic stem cell-derived therapy. Interview with Jane Lebkowski

Regen Med. 2011 Nov;6(6 Suppl):11-3. doi: 10.2217/rme.11.77.


Geron's Chief Scientific Officer, Jane Lebkowski, discusses the long road to clinical trials and the next steps for GRNOPC1. The long-awaited clinical trial of Geron's GRNOPC1 therapy for spinal cord injury has been one of the biggest stories in regenerative medicine over the past few years. The trial initially received the go-ahead from the US FDA in early 2009, but was put on clinical hold soon afterwards when an increased frequency of cysts was found in an animal experiment. Revision in release criteria and additional prospective animal studies allayed these concerns and the clinical hold was finally lifted in June 2010. The Phase I clinical trial enrolled its first patient in October 2010. As the world's first human trial of an embryonic stem cell-derived therapy, the trial has generated a huge amount of attention.

Publication types

  • Interview

MeSH terms

  • Clinical Trials as Topic*
  • Embryonic Stem Cells / transplantation*
  • Follow-Up Studies
  • Fund Raising
  • Humans
  • Information Dissemination
  • Mass Media
  • Patient Selection
  • Regenerative Medicine / economics
  • Regenerative Medicine / methods
  • Regenerative Medicine / trends
  • Spinal Cord Injuries / therapy*
  • Stem Cell Transplantation / adverse effects
  • Stem Cell Transplantation / economics
  • Time Factors